Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,491JPY
22 Jan 2018
Change (% chg)

¥25 (+0.39%)
Prev Close
¥6,466
Open
¥6,453
Day's High
¥6,491
Day's Low
¥6,430
Volume
1,349,600
Avg. Vol
1,991,814
52-wk High
¥6,693
52-wk Low
¥4,664

Latest Key Developments (Source: Significant Developments)

European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma
1:00pm GMT 

Jan 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS.TAKEDA PHARMACEUTICAL- PHASE 3 ALCANZA STUDY DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RATE OF OBJECTIVE RESPONSE LASTING ATLEAST 4 MONTHS.TAKEDA PHARMACEUTICAL CO LTD - EUROPEAN COMMISSION EXTENDED CURRENT CONDITIONAL MARKETING AUTHORIZATION OF ADCETRIS.TAKEDA PHARMACEUTICAL- EC APPROVED ADCETRIS FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY.  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES.DENALI THERAPEUTICS - TAKEDA TO MAKE AN INITIAL PAYMENT TO CO OF $150 MILLION THROUGH COMBINATION OF CASH UPFRONT PAYMENTS AND PURCHASE OF DENALI EQUITY.DENALI THERAPEUTICS - TO BE RESPONSIBLE FOR DEVELOPMENT ACTIVITIES AND COSTS PRIOR TO IND FILING FOR EACH OF THREE PROGRAMS.DENALI - WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS, INCLUDING $90 MILLION IN PRECLINICAL MILESTONES & OPT-IN PAYMENTS.DENALI THERAPEUTICS - COLLABORATION AGREEMENT TO DEVELOP,COMMERCIALIZE UP TO 3 SPECIFIED THERAPEUTIC PRODUCT CANDIDATES FOR NEURODEGENERATIVE DISEASES.DENALI - TAKEDA, CO WILL JOINTLY COMMERCIALIZE PRODUCTS IN U.S., CHINA, TAKEDA WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS IN ALL OTHER MARKETS.DENALI THERAPEUTICS - TAKEDA, CO WILL SHARE GLOBAL PROFITS FROM COLLABORATION EQUALLY.DENALI THERAPEUTICS INC - TAKEDA HAS OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE EACH OF THREE PROGRAMS.  Full Article

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion
Friday, 15 Dec 2017 

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.  Full Article

Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::OBSIDIAN THERAPEUTICS ANNOUNCES $49.5 MILLION SERIES A FINANCING TO DEVELOP CONTROLLABLE CELL AND GENE THERAPY PRODUCTS.OBSIDIAN THERAPEUTICS - SERIES A FINANCING LED BY GV, AND INCLUDED TAKEDA VENTURES, AMGEN VENTURES AMONG OTHERS.  Full Article

Takashimaya to acquire Tokyo-based real estate properties for 49.5 bln yen
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Takashimaya Co Ltd <8233.T>:Says it signs agreement with a wholly owned unit of Takeda Pharmaceutical Co Ltd <<<4502.T>>>, to acquire two Tokyo-based real estate properties as of the end of March 2019, at the price of 49.5 billion yen in total.  Full Article

Takeda Pharmaceutical unit signs agreement for sale of properties worth 49.5 bln yen
Friday, 1 Dec 2017 

Dec 1(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says its wholly owned subsidiary Takeda Pharmaceutical Real Estate Company has signed an agreement with Takashimaya Company Limited for the sale of properties.Says the sale price is 49.5 billion yen.  Full Article

Takeda Initiates Phase 1 Clinical Trial Of Zika Vaccine Candidate
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA INITIATES PHASE 1 CLINICAL TRIAL OF ZIKA VACCINE CANDIDATE.SAYS ITS ‍ZIKA VIRUS VACCINE CANDIDATE (TAK-426) HAS PROGRESSED INTO A PHASE 1 CLINICAL TRIAL​.  Full Article

U.S. FDA provides new drug safety communication on Takeda's gout drug
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - U.S. Food and Drug Administration : :U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol.U.S. FDA says once final results from Takeda Pharma are received in relation to safety clinical trial of Uloric, will conduct a comprehensive review.  Full Article

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article

LIVE MARKETS-Closing snapshot: European stocks see a bright start to the week

Jan 22 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: A BRIGHT START TO THE WEEK (1709 GMT) European stocks have closed in positive territory, while a stronger pound hampered the FTSE 100. Could this be gearing up to be week four of gains? I